DNP - Der Neurologe und Psychiater

, Volume 14, Issue 12, pp 64–69 | Cite as

Diagnose, Therapie & Risikomanagement der PML bei Multipler Sklerose

Progressive multifokale Leukenzephalopathie
Fortbildung
  • 8 Downloads

Die progressive multifokale Leukenzephalopathie spielt im neurologischen Alltag im Kontext der Eskalationstherapie der schubförmigen Multiplen Sklerose mit monoklonalen Antikörpern wieder vermehrt eine Rolle. Schwerpunkt dieser Übersicht bildet daher die Natalizumab-assoziierte PML. Sorgfältige Nutzen-Risikobewertung und Risikostratifizierung können das PML-Risiko für MS-Patienten gering halten.

Literatur

  1. 1.
    Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 1958; 81:99–111.CrossRefGoogle Scholar
  2. 2.
    Padgett BL, ZuRhein GM, Walker DL, et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1:1257–1260.PubMedCrossRefGoogle Scholar
  3. 3.
    Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain, Ferenczy et al., Clinical Microbiology Reviews 2012, 471–506.Google Scholar
  4. 4.
    Knowles WA, et al. 2003. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol. 71:115–123.PubMedCrossRefGoogle Scholar
  5. 5.
    Major EO, Neel JV. 1998. The JC and BK human polyoma viruses appear to be recent introductions to some South American Indian tribes: there is no serological evidence of cross-reactivity with the simian polyomavirus SV40. Proc. Natl. Acad. Sci. U. S. A. 95:15525–15530.PubMedCrossRefGoogle Scholar
  6. 6.
    Major EO. 2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61:35–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Delbue S, et al. 2008. Presence and expression of JCV early gene large T antigen in the brains of immunocompromised and immunocompetent individuals. J. Med. Virol. 80:2147–2152.PubMedCrossRefGoogle Scholar
  8. 8.
    Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. 2008. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann. Neurol. 64:379–387.PubMedCrossRefGoogle Scholar
  9. 9.
    Tan CS, et al. 2010. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J. Virol. 84:9200–9209.PubMedCrossRefGoogle Scholar
  10. 10.
    Tan CS, Koralnik IJ. 2010. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9:425–437.PubMedCrossRefGoogle Scholar
  11. 11.
    d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9(Suppl. 1):47–53.PubMedGoogle Scholar
  13. 13.
    Deiß, Brecht, Haarmann, Buttmann, Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 2013 Mar;13(3):313–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Clifford DB, De LA, Simpson DM, Arendt G, Giovannoni G and Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438–446.PubMedCrossRefGoogle Scholar
  15. 15.
    Berger, J.R., The clinical features of PML. Cleve Clin J Med, 2011. 78 Suppl 2: p. S8–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Natalizumab (Tysabri) and PML — the current figures www.ema.europa.eu/docs/en_GB/document_library/Presentation/2011/07/WC500109631.pdf (Zugang am 10. Sept. 2013).
  17. 17.
    Yokoyama H, Watanabe T, Maruyama D, et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008;88:443e7.Google Scholar
  18. 18.
    Shah R, Bag AK, Chapman PR, et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 2010;65:431e9.Google Scholar
  19. 19.
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M., Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov;72(5):779-87. doi: 10.1002/ana.23676.Google Scholar
  20. 20.
    Baldwin K., Hogg J., Progressive Multifocal Leukoencephalopathy in patients with Multiple Sclerosis, Curr Opin Neurol 2013, 26:318–323PubMedCrossRefGoogle Scholar
  21. 21.
    Mentzer D, Prestel J, Adams O, et al. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 2012;83:927–933.PubMedCrossRefGoogle Scholar
  22. 22.
    Joseph R. Berger, Allen J. Aksamit, David B. Clifford, et al., PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious, Neurology 2013;80;1430–1438.CrossRefGoogle Scholar
  23. 23.
    Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194:153Y64Google Scholar
  24. 24.
    Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, Campiche C, Pantaleo G, Du Pasquier RA. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology. 2012 Dec 4;79(23):2258–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemither 2009;53:1840–9.CrossRefGoogle Scholar
  26. 26.
    Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004;306:1380–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Lanzafame M, et al. 2009. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez. Med. 17:35–37.PubMedGoogle Scholar
  28. 28.
    Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS. 2011. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J. Neurol. Neurosurg. Psychiatry 82:452–455.PubMedCrossRefGoogle Scholar
  29. 29.
    Dahlhaus S, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013;84:1068–1074.PubMedCrossRefGoogle Scholar
  30. 30.
    Vermersch P, Kappos L, Gold R, Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy Neurology 2011;76;1697PubMedCrossRefGoogle Scholar
  31. 31.
    Vermersch P. Epidemiology of Natalizumab-associated PML and IRIS in MS. Presented at.: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France, 98, 10–13 October 2012.Google Scholar
  32. 32.
    Laroni A, Giacomazzi CG, Grimaldi L et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol. 2012 Sep;7(3):665–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, Linda° H, Ziemssen T, Baranzini SE, Ka¨ll T-B, Bengel D, Olsson T, Gold R, Chan A (2011) Functional energetics of CD4? -cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 6(4):e18506.PubMedCrossRefGoogle Scholar
  34. 34.
    Sandrock A, Hotermans C and Richman S. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natali-zumab treatment duration, and anti-JCV antibody status. Neurology 2011; 76(Suppl 4): A248.Google Scholar
  35. 35.
    Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Gorelik, L., et al., Anti-JC virus antibodies: implicationsfor PML risk stratification. Ann Neurol, 2010. 68(3): p. 295–303.PubMedCrossRefGoogle Scholar
  37. 37.
    Bozic C, Richman S and Plavina T. Prevalence of anti-JCV antibodies in MS patients receiving or considering treatment with natalizumab: baseline results of STRATIFY-1. Neurology 2011; 76 (Suppl 4): A598.Google Scholar
  38. 38.
    Subramanyam M, Plavina T, Lee S, Njenga M, Gorelik L, G Natarajan, et al. Anti-JCV antibodies are consistently detected prior to and after PML diagnosis in natalizumab-treated MS patients. Neurology 2011; 76: A636–A637.Google Scholar
  39. 39.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A, Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort, Neurology 2012;78;1736.PubMedCrossRefGoogle Scholar
  40. 40.
    Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013;81: 865–871.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2013

Authors and Affiliations

  1. 1.Neurologische Universitätsklinik WürzburgWürzburgDeutschland

Personalised recommendations